top of page
peptide-therapies-1024x363.jpg

A mission to bring better therapies and innovative peptide-based medicines
to improve quality of life and chronic disease management

Positioned to become a premier Peptide Therapeutics Company, driving innovation and improving lives on a global scale with the development and launch of Syracuse University's GEP-44

ozempic-inc-GettyImages-1581640516_535579_cnwthc.webp
1-removebg-preview-5.png

Peptide-based drug discovery is an important option to address common therapeutic challenges - GlucaPharm introduces 2 new peptide compound discoveries made by Syracuse University that notably reduce body weight and normalize blood glucose levels without the typical negative side effects experienced by many patients who take currently available GLP-1-based anti-obesity drugs

Image by Milad Fakurian

The Researchers at Syracuse University are Developing Innovative Therapies for Metabolic and Neurological Health:

A Next-Generation Dual-Agonist (GLP-1 & NPY) for Weight Loss and Glucose Control 

A triple-agonist peptide targeting GLP-1 and NPY1/NPY2 receptors, offering effective treatment for obesity and type 2 diabetes (T2D) without nausea or vomiting

Image by Fusion Medical Animation

The mission is to develop an effective, targeted, peptide therapy that provides potent weight loss and glucose control while preserving β-cell mass

 

Notably, what has been developed to date, delivers these benefits with minimal to no gastrointestinal disturbances or malaise, setting it apart from other GLP-1 agonists

Image by ThisisEngineering

Preclinical studies have demonstrated its equivalent efficacy to Ozempic in achieving weight loss and glucose control, with the added benefit of improved tolerability

 

 GEP44 is part of a series of chimeric peptides designed to target 2 key receptors:

(1) Neuropeptide Y-receptor (Y2-R) to reduce food intake (FI)

(2) GLP1-R to improve glucose regulation 

With potential secondary benefits that support cardiovascular health and may aid in reducing opioid addiction/withdrawal symptoms

GlucaPharm has an Exclusive Worldwide Licence
with Syracuse University to Develop GEP-44

SYRACUSE_Horizontal_1Line_ORANGE_RGB.png
ImageForArticle_24897_17175060980035167.jpg.webp

Peptide-based Therapies

For Metabolic and Neurological Diseases

Targeting Chronic Disease with Fewer Side Effects

Obesity

Diabetes

Alzheimer’s

Exploring Potential

Opioid Addiction Treatment

and Cardiovascular Health

We Believe in The Power of Expert Collaboration and 

Advanced Research, for the Development of Key Therapies that will Improve Quality of Life and Medical Care by Unlocking the Potential of Peptide Drugs

About Us

Meet the researchers and experts behind GlucaPharm and GEP-44 

weight-loss-injections-long-island.jpg
best-natural-source-peptides-for-skin-top-recommendations-658269_1600x.jpg.webp

The GEP-44 Journey In Numbers

3

Expert Researchers

2

Breakthrough Peptide Compound Discoveries -GEP44 and KCEM1

$9M

Total Grants Received

One Step Ahead in Peptide Therapeutic Research into Chronic Disease Management

bottom of page